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ObjectiveaaCHRNA7 has been shown to be a strong candidate gene for schizophrenia and bipolar disorder. It is located on chromo-
some 15q13-q14, which is one of the replicated linkage spots for schizophrenia and bipolar disorder. 
MethodsaaWe conducted an association study to determine whether previous positive association is replicable in the Korean popula-
tion. We included 254 patients with schizophrenia, 193 patients with bipolar disorder type I, 38 patients with bipolar disorder type II, 64 
schizoaffective disorder patients, and 349 controls. All subjects were ethnically Korean. A total of 898 subjects were included, and geno-
typing was done for three single nucleotide polymorphisms (SNPs) of CHRNA7. These three intronic SNPs were rs2337506 (A/G), 
rs6494223 (C/T), and rs12916879 (A/G). 
ResultsaaThere was only one marginally significant association; this association was between rs12916879 and bipolar disorder type I in 
the male subgroup. In both the allele and genotype distributions, we found a weak signal (Chi-squared=3.57, df=1, p=0.06 for allele, 
Chi-squared=7.50, df=2, p=0.02 for genotype) only. Unphased haplotype analysis could not provide additional support for this finding. 
No SNP was associated with schizophrenia or any other affected groups in this Korean sample. The associative finding is marginal and 
inconclusive. 
ConclusionaaWe could not replicate positive association in other ethnic groups previously studied. This suggests possible heterogeneity 
in the genes associated with schizophrenia and bipolar disorders. Because of structural complexity of the CHRNA7 gene and the limited 
statistical power of this study, further genetic studies with more SNPs and larger samples covering various populations, along with more 
fine molecular exploration of the CHRNA7 gene structure, are required.  Psychiatry Investig 2010;7:196-201
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INTRODUCTION
It has been observed that patients with schizophrenia are 
easily distracted by trivial sensory stimuli from the surround-
ings. This may represent disturbances in the filtering mecha-
nism for sensory stimuli in the central nervous system.
5,6 One 
auditory-evoked potential, P50, can reflect this kind of physi-
ological abnormality in sensory gaiting. P50 measures the elec-
trical brain wave with a 50-millisecond latency following pair-
ed auditory stimuli delivered 0.5 seconds apart.
4 If normal 
sensory gating has occurred, the amplitude of the second re-
sponse decreases compared with the response to the first stim-
ulus. Patients with schizophrenia showed no decrease for the 
second stimulus and a greater response than that expected in 
the normal population.
2,16 Similarly, bipolar patients with psy-
chotic features also showed diminished suppression of the P50 
auditory-evoked potential.
34 Abnormal sensory gating has been 
found to be inherited. Reduced attenuation of the P50 response 
was reported for the first-degree of relatives of individuals with 
schizophrenia, and for the relatives of individuals with bipo-
lar disorder with psychotic features.
17,38 An abnormality in P50 
was observed in mice with a dissected fimbria-fornix, and the 
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abnormality was normalized with nicotine. In patients with schi-
zophrenia, abnormal P50 was transiently normalized with nic-
otine use.
1,25 These findings are consistent with the fact that 
schizophrenics are more likely to be smokers than normal in-
dividuals. The intake of nicotine associated with smoking could 
be a self-compensation for neuro-physiological deficits.
20 
CHRNA7 has been considered a strong candidate gene for 
schizophrenia because of its function and its chromosomal lo-
cation. Abnormal activity of the CHRNA7 receptor is respon-
sible for P50 deficits. In animal models, pharmacological an-
tagonists of the CHRNA7 receptor induce the inhibitory deficit 
of P50.
30 Several studies have found decreased expression of the 
CHRNA7 gene in the postmortem human hippocampus, re-
ticular thalamic nucleus and frontal cortex of schizophrenic sub-
jects.
8,18,21 CHRNA7 gene encodes a single peptide consisting 
of an N-terminal extracellular domain, three membrane-span-
ning regions, an intracellular domain, a fourth transmembrane 
region, and an extracellular C-terminal tail. The CHRNA7 gene 
contains 10 exons and spans more than 75 kb.
19
The CHRNA7 gene is located on chromosome 15q13-q14. 
Freedman et al.
17 reported a lod score of 5.3 at a marker (D15S 
1360) on intron 2 of the CHRNA7 gene in a linkage study for 
P50. Since then, there have been many linkage studies focus-
ing on this region. The chromosome 15q13-q14 region itself is 
a strong linkage spot for both schizophrenia and bipolar dis-
order. Many positive linkage findings, as well as several negative 
studies, exist for schizophrenia in this chromosomal region.
26 
One meta-analysis for schizophrenia supported positive link-
age association,
3 but another meta-analysis did not.
28 For bipo-
lar disorder, linkage disequilibrium at D15S1360 and linkage 
at 15q13-q14 have been reported.
11,32 Age at onset and a good 
response to lithium also have been mapped to this region.
13,39 
Within the CHRNA7 gene, many single nucleotide polymor-
phisms (SNPs) in exons, introns and promoter sites have been 
tested for association with schizophrenia and bipolar disorder, 
and these experiments have produced conflicting results.
22,26,27 
There has been no genetic study on the CHRNA7 gene and 
schizophrenia or bipolar disorder for the Korean population. 
We conducted this study in order to further explore the role of 
the CHRNA7 gene by attempting to replicate previous posi-
tive association between the CHRNA7 gene and schizophre-
nia and bipolar disorder in a Korean sample. 
METHODS
Patients were recruited from the Seoul National University 
Hospital and several psychiatric clinics in Korea. All patients 
satisfied the diagnostic criteria of DSM-IV for schizophrenia 
and bipolar disorder. They were individually interviewed by 
trained nurses using the Korean version of Diagnostic Inter-
view for Genetic Studies.
24,33 Consensus diagnostic meetings of 
more than three psychiatrists were held regularly to make the 
participants’ final diagnoses. Subjects with a history of any kind 
of organic abnormality of the brain, substance dependence, 
drug abuse, or other physical conditions possibly manifesting 
psychiatric symptoms were excluded from this study. The final 
analyses were performed with 549 patients and 349 controls. 
The patient group consisted of 254 patients with schizophrenia, 
193 patients with bipolar disorder type I, 38 patients with bi-
polar disorder type II, and 64 patients with schizoaffective dis-
order. Healthy controls were free from present, past and family 
history (first-degree relatives) of psychiatric illness or substance 
abuse diagnoses. The total number of control subjects was 349 
(174 males and 175 females). The mean ages of the patient and 
control groups were 35.09±10.27 and 25.92±6.57 years, respec-
tively. More detailed information regarding subject number 
and mean age for each diagnostic group is given in Table 1. All 
subjects participating in this study signed a written informed 
consent form, and the study protocol was approved by the eth-
ics committee of Seoul National University Hospital.
Deoxyribonucleic acid (DNA) was extracted from blood 
samples using a DNA isolation kit (Roche, Mannheim, Ger-
many). We selected three intronic SNPs for the CHRNA7 gene: 
rs2337506, rs6494223, and rs12916879. These SNPs were se-
lected based on chromosomal location, minor allele frequen-
cies in Asians, and linkage disequilibrium (LD), according to 
public information such as Entrez SNP of National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.gov/
snp). Even though the number of SNPs was so limited to cov-
er the whole CHRNA7 gene, we tried to include representa-
Table 1. Number of subjects and mean age for each diagnostic group
Group
Number of subjects Age (Mean, SD)
Total Male Female Total Male Female
SZ 254 152 102 35.56 (8.21)0 34.68 (7.66)0 36.86 (8.86)0
BP I 193 082 111 36.79 (12.55) 37.38 (13.28) 36.35 (12.02)
BP II 038 017 021 36.08 (8.71)0 35.18 (7.84)0 36.81 (9.47)0
SA 064 028 036 31.94 (11.59) 30.54 (10.34) 33.03 (12.51)
Control 349 174 175 25.92 (6.57)0 24.98 (5.26)0 26.85 (7.55)0
SZ: schizophrenia, BP I: bipolar disorder type I, BP II: bipolar disorder type II, SA: schizoaffective disorder, SD: standard deviation198  Psychiatry Investig 2010;7:196-201
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tive SNPs of the whole gene and choose the closer SNP to the 
markers previously studied for schizophrenia and bipolar 
disorder. Rs2337506 (chr15:32,345,817-32,346,317bp) is locat-
ed inside intron 2, rs6494223 (chr15:32,396,207-32,396,707bp) 
is located in intron 3, and rs12916879 is located in intron 4 
(chr15:32,417,083-32,417,583bp). According to the haplotype 
information in Caucasians, these three SNPs are in separate 
haplotype blocks.
7 The D15S1360 microsatellite marker, which 
is the most frequently studied and reported to be associated 
with schizophrenia and bipolar disorder, is located in intron 2. 
Therefore SNP rs2337506 is close to D15 S1360 (chr15:30,143,950- 
30,144,057) and is likely to be in LD. Genotyping was performed 
using the TaqMan
TM method (Applied Biosystems, Foster City, 
CA, USA).
31 The chromosomal location of SNPs were adapted 
from UCSC Genome Browser on Human Feb. 2009 (GRCh37/
hg19) Assembly (http://genome.ucsc.edu/).
Hardy-Weinberg equilibrium was tested by goodness-of-
fit chi-squared test. Contingency chi-squared tests were per-
formed for the comparison of allele and genotype frequencies 
between the patients and controls using Statistical Package 
for the Social Sciences (SPSS)(version 13.0; SPSS Inc., Chica-
go, IL, USA). The haplotype analyses were done using UN-
PHASED 3.0.13 (http://www.mrc-bsu.cam.ac.uk/personal/
frank/software/unphased/).
11 The haplotype association was 
tested for two to three SNPs with the sliding window method. 
In this study, the program calculated chi-squared values and 
p-values for a specific haplotype association according to the 
main haplotype effect model. The level of statistical significance 
was set at p=0.05. Genetic Power Calculator (http://pngu.mgh.
harvard.edu/~purcell/gpc)
35 was used to compute the statisti-
cal power of our sample.
RESULTS
The allele and genotype distributions in both the whole pa-
tient and control groups were in Hardy-Weinberg equilibrium 
for the three selected SNPs (data not shown). The whole pa-
tient group included the patients with schizophrenia, bipolar 
disorder type I and type II, and schizoaffective disorder. For 
the analysis, all patients were regrouped into several affected 
groups: a group of patients with schizophrenia, a group of pa-
tients with bipolar disorder type I only, a group of patients 
with bipolar disorder type I and type II, a group of patients 
with bipolar disorder type I, II and schizoaffective disorder, 
and a group of all the patients. However, in the tables, the raw 
data are shown according to each diagnostic group and not ac-
cording to the testing group in order to provide the exact count 
of alleles and genotypes for each diagnostic group (Table 2 and 3). 
There was no allelic association found for either schizophre-
nia or bipolar disorder. Additional analysis according to sex 
did not find any association for any of the three SNPs. Only 
one marginally significant association was found; this associ-
ation was between rs12916879 and bipolar disorder type I in 
the male subgroup (Chi-squared=3.57, df=1, p=0.06). Table 2 
shows the allele distribution for the three SNPs of the CHR-
NA7 gene for each diagnostic group. The genotype distribu-
tion for each diagnostic group is presented in Table 3. In the 
total sample (male and female), no significant association 
with genotype distribution was observed for any of the SNPs. 
When we divided the groups by sex, rs12916879 was signifi-
cantly associated with bipolar disorder type I (p=0.02) only in 
males. The degree of significance was reduced if the analysis 
was extended to include bipolar disorder type II and schizoaf-
fective disorder (BPD type I & II, p=0.05, BPD type I, II & SA, 
p=0.05). There was no genotypic association for any of the 
three SNPs in females for any diagnostic group. No SNP was 
associated with schizophrenia or any other affected groups in 
this sample.
Since a positive association with a single SNP was found 
only in males, further haplotype analysis was performed only 
for males. Table 4 summarizes the global D’ and association 
statistics between SNPs. No haplotype was significantly asso-
ciated with bipolar disorder. In the effort to reduce the possi-
ble influence of multiple testing, a permutation test was per-
formed using the UNPHASED genetic analysis software. One 
thousand permutations were conducted for the male bipolar 
Table 2. Allele distribution for three SNPs of CHRNA7
Group
rs2337506 (A/G) rs6494223 (C/T) rs12916879 (A/G)
Total Male Female  Total Male Female   Total Male Female
A1 A2 A1 A2 A1 A2 A1 A2 A1 A2 A1 A2 A1 A2 A1 A2 A1 A2
SZ 386 120 232 70 154 50 204 302 113 189 91 113 352 154 204 98 148 56
BP I 293 93 126 38 167 55 152 234 68 96 84 138 244 140 103 61 141 79
BP II 54 20 23 9 31 11 33 43 11 23 22 20 54 20 23 9 31 11
SA 91 37 42 14 49 23 55 73 27 29 28 44 96 32 45 11 51 21
Control 533 165 265 83 268 82 288 410 142 206 146 204 483 215 240 108 243 107
Total 1,357 435 688 214 669 221 732 1,062 361 543 371 519 1,229 561 615 287 614 274
SZ: schizophrenia, BP I: bipolar disorder type I, BP II: bipolar disorder type II, SA: schizoaffective disorderEJ Joo et al. 
   www.psychiatryinvestigation.org  199
disorder type I subgroup and for controls. The adjusted p-
value from the permutation test was 0.28 (standard error= 
0.01).
DISCUSSION
We found a positive genotypic association between bipolar 
disorder type I and SNP rs12916879 in the male subgroup. 
However, the association was not supported by allele or hap-
lotype, and the significance could not survive correction for 
multiple testing. For schizophrenia, we could not find any as-
sociation with CHRNA7 in this Korean sample. As a whole, 
we could not replicate the positive association of CHRNA7 
with either schizophrenia or bipolar disorder in this Korean 
sample. This association study does not support a strong ge-
netic role of CHRNA7 in schizophrenia and bipolar disorder.
This result indirectly supports the well-known genetic het-
erogeneity among various populations for both bipolar disor-
der and schizophrenia. There are many positive linkage and asso-
ciation findings for this chromosomal region in various ethnic 
populations.
26 However, these associations have not been support-
ed in Asian populations. There has been a report of a positive li-
nkage for Han Chinese patients between schizophrenia and the 
chromosome 15q14 region.
29 However, two negative associa-
tion studies in the Han Chinese population have been published 
so far.
12,23 To the best of our knowledge, there has been no pub-
lished result on Japanese patients with schizophrenia. 
It is well known that there is a difference in allele frequen-
cies between various ethnic populations. In this Korean sam-
ple, the allele frequencies of three SNPs of the CHRNA7 gene 
were similar to the allele frequencies of Han Chinese and Jap-
anese populations reported in Entrez SNP: A in SNP rs2337506 
(0.76) is 0.66 for Japanese and 0.77 for Han Chinese, T in SNP 
rs6494223 (0.59) is 0.76 for Japanese and 0.67 for Han Chi-
nese, and A in SNP rs12916879 (0.69) is 0.64 for Japanese and 
0.71 for Han Chinese. 
Chromosome 15q13-14, as well as the CHRNA7 gene, has a 
complex structure. Exons 5 to 10 of CHRNA7 are known to 
be duplicated and located in the opposite direction. This du-
plication and inversion creates CHRFAM7A, an alpha 7-like 
nicotinic receptor subunit gene. This gene is a hybrid of CHR-
NA7 and several copies of an unrelated genetic sequence FA-
M7A.
15 The duplication, a type of copy number variant, is not 
present in all subjects. About 30% of individuals have only 
one copy, and more than 5% have no copies.
19,37 There is 2-bp 
deletion polymorphism in exon 6 of CHRFAM7A, which is 
tightly linked to the duplication-inversion polymorphism.
15 
Previous studies using this 2-bp deletion polymorphism as a 
surrogate marker for the copy number variant of CHRNA7 
have been conducted. In French Caucasians, this 2-bp deletion 
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was a risk factor for P50 sensory gating deficits.
36 Flomen et 
al.
14 could not find an association between this 2-bp deletion 
polymorphism and schizophrenia or bipolar disorder in the 
Scottish population. The presence of the 2-bp deletion was as-
sociated with poor performance in episodic memory tests in 
the family members of individuals with schizophrenia.
9 This 
kind of complex genetic structure probably contributes to 
the discrepancies in the current linkage and/or association re-
sults for psychiatric disorders. The three SNPs of this study 
are located in intron 2, 3 and 4, not in duplicated region of the 
gene. Unfortunately, we could not examine this 2-bp deletion 
polymorphism. Since the 2-bp deletion strongly represents 
the complicated structure of CHRNA7, further studies that 
include this polymorphism will be crucial to understand the 
role of CHRNA7 as well as the whole chromosomal region of 
15q13-14.
This study has considerable limitations. First, the sample 
size was not large enough to detect small gene effects. Consid-
ering the minor allele as a risk allele and given the significance 
level of α=0.05, our analysis had a power of 47-61% for schizo-
phrenia, and 41-55% for bipolar disorder type I under a domi-
nant model (genotypic relative risk of AA=1.5; prevalence= 
0.01 for both schizophrenia and bipolar disorder type I). There-
fore, we admit that our study sample was limited in statistical 
power, even though this sample size was not relatively small. 
Second, we included only three SNPs of CHRNA7, which do 
not represent the whole CHRNA7 gene. Third, this study did 
not include SNPs in the promoter site or the 2-bp deletion in 
exon 6, both of which have been reported to have meaning-
ful associations in other population samples. Fourth, our con-
trol group was significantly younger than the patient group, 
and we could not exclude the possibility of future development 
of schizophrenia and/or bipolar disorder among this control 
group. Finally, the population stratification should be kept in 
mind for every association study, even though the Korean pop-
ulation is considered relatively less heterogeneous. 
CHRNA7, which is located on chromosome 15q13-14, has a 
complex genetic structure and has been frequently implicated 
in many psychiatric illnesses. Because there are remarkable in-
consistencies in the results from previous studies, and because 
many of them had insufficient statistical power, it is necessary 
to conduct further research on the CHRNA7 gene with respect 
to schizophrenia and bipolar disorder with sufficient statisti-
cal power in many other populations. We hope the data of this 
study will contribute to the future meta-analysis, although the 
power of this study alone is not enough to detect any genetic as-
sociation. 
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